In the original article, there was an error. Themanuscript states that “Apixaban and edoxaban need to be administered twice a day” whereas Edoxaban needs to be administered only once a day as stated in the European Product Information and Summary of Product Characteristics. A correction has been made to the section PHARMACOKINETIC OF DOACS, subsection Direct Factor Xa Inhibitors: “Apixaban, edoxaban and rivaroxaban are selective inhibitors of Xa factor (FXa) by binding its active site both when free or thrombin-bound..
ASJC Scopus subject areas
- Clinical Neurology